Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 14/20 | 0.74 |
| ▸ | PRKDC | P78527 | 5/20 | 0.74 |
| ▸ | ATM | Q13315 | 2/20 | 0.74 |
| ▸ | GRM5 | P41594 | 6/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19101052 | 0.85 | ATR (1.00) | ATRPRKDCATM | |
| SCHEMBL3868552 | 0.82 | GRM5 (0.71) | ATRPRKDCATMGRM5 | |
| SCHEMBL3861278 | 0.80 | ATR (0.84) | ATRPRKDCATMGRM5 | |
| SCHEMBL19101068 | 0.80 | ATR (0.70) | ATRPRKDCATM | |
| SCHEMBL11907363 | 0.80 | ATR (0.74) | ATRPRKDCATM | |
| SCHEMBL2486705 | 0.77 | ATR (0.80) | ATRPRKDCATM | |
| SCHEMBL2510800 | 0.77 | ATR (1.00) | ATRPRKDCGRM5 | |
| SCHEMBL8283077 | 0.77 | GRM5 (0.78) | ATRGRM5 | |
| SCHEMBL3861333 | 0.76 | GRM5 (1.00) | ATRGRM5 | |
| SCHEMBL3870528 | 0.75 | GRM5 (1.00) | ATRGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1715867-A4 | BIPYRIDYL AMIDES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO INC (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20070149547-A1 | Bipyridyl amides as modulators of metabotropic glutamate receptor-5 | MERCK SHARP & DOHME CORP. | 2007-06-28 | — | — | US | disclosed |
| US-20070149547-A1 | Bipyridyl amides as modulators of metabotropic glutamate receptor-5 | MERCK SHARP & DOHME CORP. | 2007-06-28 | — | — | US | disclosed |
| US-20070149547-A1 | Bipyridyl amides as modulators of metabotropic glutamate receptor-5 | MERCK SHARP & DOHME CORP. | 2007-06-28 | — | — | US | disclosed |
| EP-1715867-A1 | BIPYRIDYL AMIDES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Merck & Co., Inc. (US) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005079802-A1 | BIPYRIDYL AMIDES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO., INC. (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149547-A1 | Bipyridyl amides as modulators of metabotropic glutamate receptor-5 | GRM5, GRIK5, GABRA5 | ATR 3153/4885PRKDC 4859/4885ATM 4580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.